141 related articles for article (PubMed ID: 7545380)
1. The effect of 6% hydroxyethyl starch and desmopressin infusion on von Willebrand factor: ristocetin cofactor activity.
Lazarchick J; Conroy JM
Ann Clin Lab Sci; 1995; 25(4):306-9. PubMed ID: 7545380
[TBL] [Abstract][Full Text] [Related]
2. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
3. Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease.
Mohri H; Hashimoto Y; Yamazaki E; Kanamori H; Okubo T
Hematopathol Mol Hematol; 1998; 11(2):109-15. PubMed ID: 9608359
[TBL] [Abstract][Full Text] [Related]
4. [Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis].
Köhler M; Kotitschke R; Braun B; Hellstern P; Mörsdorf S; Pindur G; Heiden M; Wenzel E
Beitr Infusionsther; 1990; 26():136-41. PubMed ID: 1703813
[TBL] [Abstract][Full Text] [Related]
5. Mild forms of von Willebrand disease: diagnosis and management.
Federici AB
Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308
[TBL] [Abstract][Full Text] [Related]
6. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
[TBL] [Abstract][Full Text] [Related]
7. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willebrand disease.
Gill JC; Ottum M; Schwartz B
J Pediatr; 2002 May; 140(5):595-9. PubMed ID: 12032528
[TBL] [Abstract][Full Text] [Related]
9. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
[TBL] [Abstract][Full Text] [Related]
10. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
11. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
[TBL] [Abstract][Full Text] [Related]
12. [Von Willebrand disease: characteristics and response to desmopressin. Study of 103 cases].
César JM; Avello AG; Vecino A; Cerveró C; Laraña JG; Fuertes IF; Villarrubia J; López J; de Oteyza JP; Velasco JL; Cantalapiedra A; Herrera P; Herrero S; Navarro JL
Med Clin (Barc); 1998 Nov; 111(16):601-3. PubMed ID: 9881332
[TBL] [Abstract][Full Text] [Related]
13. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies.
Favaloro EJ
Semin Thromb Hemost; 2006 Sep; 32(6):566-76. PubMed ID: 16977567
[TBL] [Abstract][Full Text] [Related]
14. A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery.
Hackmann T; Gascoyne RD; Naiman SC; Growe GH; Burchill LD; Jamieson WR; Sheps SB; Schechter MT; Townsend GE
N Engl J Med; 1989 Nov; 321(21):1437-43. PubMed ID: 2682243
[TBL] [Abstract][Full Text] [Related]
15. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
16. 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease.
McKeown LP; Connaghan G; Wilson O; Hansmann K; Merryman P; Gralnick HR
Am J Hematol; 1996 Feb; 51(2):158-63. PubMed ID: 8579058
[TBL] [Abstract][Full Text] [Related]
17. Acquired von Willebrand's syndrome: a single institution experience.
Kumar S; Pruthi RK; Nichols WL
Am J Hematol; 2003 Apr; 72(4):243-7. PubMed ID: 12666134
[TBL] [Abstract][Full Text] [Related]
18. Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects.
de Jonge E; Levi M; Büller HR; Berends F; Kesecioglu J
Intensive Care Med; 2001 Nov; 27(11):1825-9. PubMed ID: 11810130
[TBL] [Abstract][Full Text] [Related]
19. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
20. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
Frank RD; Kunz D; Wirtz DC
Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
